Developer docs
API playgroundTry for free, no card

Search company profiles

MedVector

Full company profile

uuid000314b

Namestring
MedVector
Legal namestring
MedVector Corp
Websiteurl
medvector.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

MedVector is a privately held U.S. clinical trial technology company founded around 2017 and headquartered in El Segundo, California, that enables treating physicians to host decentralized clinical trial appointments from their local practices without becoming investigators or triggering new clinical trial sites. The company's core offering is its proprietary Prime-Control Technology platform — a HIPAA-compliant telemedicine system packaged in a shoebox-sized plug-and-play device that is shipped to a subject's local healthcare provider prior to a study visit. The device automatically connects to the appropriate clinical trial site, allowing the principal investigator to virtually monitor the subject face-to-face while a local nurse serves as the PI's delegated "hands" for blood draws, vitals, and other procedures. Critically, source data is entered directly into the EDC at the clinical trial site by the investigator team rather than through MedVector, a design choice the company cites as preserving FDA Electronic Source Data guidance compliance (September 2013), GCP adherence, and the integrity of the trial's regulatory record.

MedVector operates a "first-of-kind HCP Recruitment" go-to-market model, identifying local specialists who should be referring patients to clinical trials but are not, and onboarding them as alternative visit locations for specific protocols. Around this backbone, the company offers a clinical trial site-utility service that allows community physicians to "prescribe" trials as a care option, a Patient Enrollment Expansion Solution, and the physical Turnkey Trial Visits device — all described as facets of the same Prime-Control backbone rather than separate products.

The business model is service-based and enterprise-oriented: MedVector partners with CROs, pharmaceutical sponsors, and patient recruitment companies, with revenue generated by pharma sponsors paying for protocol-specific expansion services and study-specific tests performed at physician offices. Pricing is custom and not publicly disclosed. The company has supplemented its capital base through multiple funding rounds (cumulative disclosed funding of roughly $4.66M across 2018–2024, including approximately $492,000 raised from 227 retail investors via StartEngine equity crowdfunding at a $10 million valuation) and has assembled a senior advisory bench including Craig Lipset (former Pfizer Head of Clinical Innovation, DTRA co-chair) and John Neal (founder/chairman of PCRS Network). Headcount is reported at 1–10 employees and only one named enterprise customer (Novartis) appears in disclosed case material.

Short descriptiontext

MedVector is a privately held U.S. clinical trial technology company whose Prime-Control platform enables treating physicians to host decentralized trial visits at their local practices via a plug-and-play telemedicine device, serving pharma sponsors, CROs, and clinical trial sites.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEl Segundo, United States
HQ citystring
El Segundo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
decentralized clinical trials, clinical trial telemedicine, patient recruitment services, HCP recruitment platform, trial site expansion technology
Industry4 codes
PRIMARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALACAK
Pharmacy/Medication Management & Virtual MTM (Payer-Sponsored)
Healthcare & Life Sciences/Telehealth Platforms/Payer-Sponsored Virtual Care Platforms
SECONDARYHLALAAAD
Prescription-Based Digital Clinics (Condition-Specific Rx Programs)
Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code2 codes
  • Offices of Physicians62111
  • Home Health Care Services62161
SIC code2 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Health Services8000
Product category
Decentralized Clinical Trial Technology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Trial Expansion Services for Pharma Sponsors and CROs
TypeProfessional Services
Description

MedVector generates revenue by partnering with CROs, pharmaceutical sponsors, and patient recruitment companies to deploy its Prime-Control Technology, expanding subject participation beyond existing clinical trial sites. Revenue model is service-based, paid by pharma sponsors who pay for the trial expansion services. Generators of revenue include study-specific tests performed at physician offices, paid for by Pharma.

medvector.com
2StartEngine Equity Crowdfunding
TypeTransaction Fee
Description

MedVector conducted a public equity crowdfunding raise on StartEngine, raising over $492,000 from 227 investors at a $10 million valuation with a minimum investment of $495.90. This was a one-time capital raise rather than ongoing revenue.

medvector.com
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Custom enterprise engagement - quote-based
ModelOther
Notes

Pricing not publicly disclosed. Free protocol analysis offered ("there is no cost for MedVector analysis"). Engagement scope and pricing is custom per study/protocol.

medvector.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Prime-Control Technology
Description

Proprietary telemedicine platform / embedded software shipped as a shoebox-sized plug-and-play device enabling clinical trial sites to virtually monitor subjects face-to-face at local providers' offices.

medvector.com
Core offering1 text field

MedVector provides a proprietary telemedicine platform, Prime-Control Technology, that enables clinical trial sites to virtually monitor subjects face-to-face at their local healthcare providers' offices without triggering new clinical trial sites or investigators. MedVector ships a shoebox-sized plug-and-play device to the subject's local HCP so a Principal Investigator (PI) can run the session remotely while the local nurse serves as the PI's "hands" for vitals, blood draws, and procedures. Source data is still entered into the trial site's EDC by the investigator team, preserving Good Clinical Practice (GCP).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

MedVector is a single-platform clinical trial site-utility, not a multi-module suite. Its offering centers on the proprietary Prime-Control Technology platform, a turnkey telemedicine/HCP-recruitment model in which MedVector ships a shoebox-sized plug-and-play device to a subject's local healthcare provider so a clinical trial site's principal investigator (PI) can virtually monitor the subject face-to-face while the local nurse serves as the PI's "hands." Wrapped around Prime-Control are the MedVector clinical-trial-site-utility service (allowing community physicians to "prescribe" trials as a care option without becoming investigators), the Patient Enrollment Expansion Solution (HIPAA-compliant telemedicine for finding and recruiting diverse patients), the HCP Recruitment service (identifying and onboarding local specialists who should be referring but aren't), and the physical Turnkey Trial Visits device. All of these are facets of the same Prime-Control backbone rather than separate products.

Product and service4 records
1Prime-Control Technology Platform
CategoryDecentralized Clinical Trial Platform (Core)
Description

Proprietary telemedicine platform that connects a clinical trial site with a subject's local, non-investigator healthcare provider (HCP). MedVector ships a shoebox-sized plug-and-play device to the local HCP, allowing the Principal Investigator (PI) to virtually monitor subjects face-to-face while a local nurse serves as the PI's "hands" for vitals, blood draws, and procedures. Data is entered by the investigator team into the trial site's existing EDC, preserving Good Clinical Practice (GCP) and FDA-compliant source data location. For pharmaceutical sponsors and CROs seeking to expand enrollment without triggering new clinical trial sites or new investigators.

2HCP Recruitment Service
CategoryPatient Recruitment Service
Description

First-of-kind service offering that identifies and onboards local specialists who should be referring patients to clinical trials but aren't, then activates them as alternative MedVector visit locations for specific qualifying protocols. Coordinates all logistics between the clinical trial site and alternative locations; training is provided at clinical trial sites with no training required at alternative locations. For pharmaceutical sponsors and CROs seeking to expand the referring physician pool for trial enrollment.

3Turnkey Trial Visits Device
CategoryTelemedicine Hardware / Device
Description

Physical plug-and-play telemedicine device shipped to a subject's local healthcare provider prior to a trial appointment. The unit automatically connects to the appropriate clinical trial site, allowing the Principal Investigator to control the entire live session as if co-located with the subject. The local nurse performs generic procedures (blood draws, vital signs) under the PI's delegated authority. The hardware underpinning MedVector's Prime-Control platform.

4Patient Enrollment Expansion Solution
CategoryPatient Enrollment / Trial Expansion Service
Description

HIPAA-compliant, plug-and-play telemedicine solution for clinical trials that provides tools for finding and recruiting patients, collecting data, and performing analysis across dosage forms including pills, sprays, inhalers, creams, drops, and self-injectable medications. A Novartis case study demonstrated recruitment completed in seven weeks. For pharmaceutical sponsors and CROs seeking faster, more diverse enrollment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Fully decentralized clinical trial platform combining telehealth, connected devices, and home-based nurse visits for sponsors. Comparable as a DCT vendor competing for the same hybrid visit and remote monitoring budgets.

TypeBroad incumbent
Description

Enterprise cloud software provider for the life sciences industry, including CTMS, EDC, and eTMF used by clinical trial sponsors and CROs. Comparable as an adjacent incumbent whose ecosystem decisions shape DCT adoption and integration paths.

TypeDirect peer
Description

Decentralized clinical trial software platform enabling sponsors to run studies in participants' homes with connected devices and remote coordinators. Comparable to MedVector as a competing DCT platform for pharma/CRO customers.

TypeBroad incumbent
Description

Global CRO and clinical technology services provider with a dedicated decentralized clinical trial practice. Comparable as a broad incumbent offering site-less and hybrid trial services to pharma sponsors.

TypeEmerging player
Description

Clinical trial site enablement platform providing eRegulatory, eISF, and remote site connectivity tools. Comparable as an emerging enabler focused on site-side workflow, overlapping with MedVector's site-preserving positioning.

TypeBroad incumbent
Description

Clinical trial technology provider offering eCOA, eConsent, patient engagement, and decentralized trial solutions. Comparable as an incumbent DCT/eCOA vendor competing for shared sponsor budgets.

TypeBroad incumbent
Description

Large clinical trial technology vendor offering eCOA, cardiac safety, imaging, and decentralized trial solutions. Comparable as a broader incumbent offering overlapping DCT/remote visit capabilities to the same pharma/CRO buyers.

TypeDirect peer
Description

Decentralized clinical trial platform offering telehealth, in-home nurse visits, and connected devices for remote trial conduct. Directly comparable to MedVector as a DCT infrastructure player; the two compete for the same pharma/CRO sponsors seeking remote visit capabilities.

TypeDirect peer
Description

DCT and eCOA platform supporting decentralized study execution, remote visits, and connected device integrations. Comparable as a competing DCT infrastructure provider in the same pharma/CRO market.

TypeDirect peer
Description

Patient-centric DCT platform providing eConsent, eCOA, telehealth, and remote data capture. Comparable to MedVector as a competing DCT infrastructure vendor targeting pharma sponsors and CROs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MedVector

Decentralized Clinical Trial Technologymedvector.com

MedVector is a privately held U.S. clinical trial technology company whose Prime-Control platform enables treating physicians to host decentralized trial visits at their local practices via a plug-and-play telemedicine device, serving pharma sponsors, CROs, and clinical trial sites.

What MedVector does

MedVector is a privately held U.S. clinical trial technology company founded around 2017 and headquartered in El Segundo, California, that enables treating physicians to host decentralized clinical trial appointments from their local practices without becoming investigators or triggering new clinical trial sites. The company's core offering is its proprietary Prime-Control Technology platform — a HIPAA-compliant telemedicine system packaged in a shoebox-sized plug-and-play device that is shipped to a subject's local healthcare provider prior to a study visit. The device automatically connects to the appropriate clinical trial site, allowing the principal investigator to virtually monitor the subject face-to-face while a local nurse serves as the PI's delegated "hands" for blood draws, vitals, and other procedures. Critically, source data is entered directly into the EDC at the clinical trial site by the investigator team rather than through MedVector, a design choice the company cites as preserving FDA Electronic Source Data guidance compliance (September 2013), GCP adherence, and the integrity of the trial's regulatory record.

MedVector operates a "first-of-kind HCP Recruitment" go-to-market model, identifying local specialists who should be referring patients to clinical trials but are not, and onboarding them as alternative visit locations for specific protocols. Around this backbone, the company offers a clinical trial site-utility service that allows community physicians to "prescribe" trials as a care option, a Patient Enrollment Expansion Solution, and the physical Turnkey Trial Visits device — all described as facets of the same Prime-Control backbone rather than separate products.

The business model is service-based and enterprise-oriented: MedVector partners with CROs, pharmaceutical sponsors, and patient recruitment companies, with revenue generated by pharma sponsors paying for protocol-specific expansion services and study-specific tests performed at physician offices. Pricing is custom and not publicly disclosed. The company has supplemented its capital base through multiple funding rounds (cumulative disclosed funding of roughly $4.66M across 2018–2024, including approximately $492,000 raised from 227 retail investors via StartEngine equity crowdfunding at a $10 million valuation) and has assembled a senior advisory bench including Craig Lipset (former Pfizer Head of Clinical Innovation, DTRA co-chair) and John Neal (founder/chairman of PCRS Network). Headcount is reported at 1–10 employees and only one named enterprise customer (Novartis) appears in disclosed case material.

MedVector firmographics

Firmographics
Name
MedVector
Legal name
MedVector Corp
Website
https://medvector.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
MedVector is a privately held U.S. clinical trial technology company whose Prime-Control platform enables treating physicians to host decentralized trial visits at their local practices via a plug-and-play telemedicine device, serving pharma sponsors, CROs, and clinical trial sites.
Ownership category
akta.pro rank

MedVector industry classification

Industry
Product category
Decentralized Clinical Trial Technology
NAICS
Offices of Physicians (62111), Home Health Care Services (62161)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
akta.pro industry
PRIMARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALACAK
Pharmacy/Medication Management & Virtual MTM (Payer-Sponsored)
Healthcare & Life Sciences/Telehealth Platforms/Payer-Sponsored Virtual Care Platforms
SECONDARYHLALAAAD
Prescription-Based Digital Clinics (Condition-Specific Rx Programs)
Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Decentralized clinical trials
  • Clinical trial telemedicine
  • Patient recruitment services
  • HCP recruitment platform
  • Trial site expansion technology

Where MedVector is headquartered

Location

Headquarters

HQ city
El Segundo
HQ country
United States
HQ region
North America

Markets served

MedVector business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Clinical Trial Expansion Services for Pharma Sponsors and CROs: MedVector generates revenue by partnering with CROs, pharmaceutical sponsors, and patient recruitment companies to deploy its Prime-Control Technology, expanding subject participation beyond existing clinical trial sites. Revenue model is service-based, paid by pharma sponsors who pay for the trial expansion services. Generators of revenue include study-specific tests performed at physician offices, paid for by Pharma.
  2. StartEngine Equity Crowdfunding: MedVector conducted a public equity crowdfunding raise on StartEngine, raising over $492,000 from 227 investors at a $10 million valuation with a minimum investment of $495.90. This was a one-time capital raise rather than ongoing revenue.

Pricing tiers

ModelBillingPrice
Other—Custom enterprise engagement - quote-based

Go-to-market motion1 record

MedVector product offering

Product offering

Core offering

MedVector provides a proprietary telemedicine platform, Prime-Control Technology, that enables clinical trial sites to virtually monitor subjects face-to-face at their local healthcare providers' offices without triggering new clinical trial sites or investigators. MedVector ships a shoebox-sized plug-and-play device to the subject's local HCP so a Principal Investigator (PI) can run the session remotely while the local nurse serves as the PI's "hands" for vitals, blood draws, and procedures. Source data is still entered into the trial site's EDC by the investigator team, preserving Good Clinical Practice (GCP).

Product overview

MedVector is a single-platform clinical trial site-utility, not a multi-module suite. Its offering centers on the proprietary Prime-Control Technology platform, a turnkey telemedicine/HCP-recruitment model in which MedVector ships a shoebox-sized plug-and-play device to a subject's local healthcare provider so a clinical trial site's principal investigator (PI) can virtually monitor the subject face-to-face while the local nurse serves as the PI's "hands." Wrapped around Prime-Control are the MedVector clinical-trial-site-utility service (allowing community physicians to "prescribe" trials as a care option without becoming investigators), the Patient Enrollment Expansion Solution (HIPAA-compliant telemedicine for finding and recruiting diverse patients), the HCP Recruitment service (identifying and onboarding local specialists who should be referring but aren't), and the physical Turnkey Trial Visits device. All of these are facets of the same Prime-Control backbone rather than separate products.

Differentiator

Problem solved

Functional benefit

Brands

  • Prime-Control Technology: Proprietary telemedicine platform / embedded software shipped as a shoebox-sized plug-and-play device enabling clinical trial sites to virtually monitor subjects face-to-face at local providers' offices.

Products and services

  • Prime-Control Technology Platform Proprietary telemedicine platform that connects a clinical trial site with a subject's local, non-investigator healthcare provider (HCP). MedVector ships a shoebox-sized plug-and-play device to the local HCP, allowing the Principal Investigator (PI) to virtually monitor subjects face-to-face while a local nurse serves as the PI's "hands" for vitals, blood draws, and procedures. Data is entered by the investigator team into the trial site's existing EDC, preserving Good Clinical Practice (GCP) and FDA-compliant source data location. For pharmaceutical sponsors and CROs seeking to expand enrollment without triggering new clinical trial sites or new investigators.
  • HCP Recruitment Service First-of-kind service offering that identifies and onboards local specialists who should be referring patients to clinical trials but aren't, then activates them as alternative MedVector visit locations for specific qualifying protocols. Coordinates all logistics between the clinical trial site and alternative locations; training is provided at clinical trial sites with no training required at alternative locations. For pharmaceutical sponsors and CROs seeking to expand the referring physician pool for trial enrollment.
  • Turnkey Trial Visits Device Physical plug-and-play telemedicine device shipped to a subject's local healthcare provider prior to a trial appointment. The unit automatically connects to the appropriate clinical trial site, allowing the Principal Investigator to control the entire live session as if co-located with the subject. The local nurse performs generic procedures (blood draws, vital signs) under the PI's delegated authority. The hardware underpinning MedVector's Prime-Control platform.
  • Patient Enrollment Expansion Solution HIPAA-compliant, plug-and-play telemedicine solution for clinical trials that provides tools for finding and recruiting patients, collecting data, and performing analysis across dosage forms including pills, sprays, inhalers, creams, drops, and self-injectable medications. A Novartis case study demonstrated recruitment completed in seven weeks. For pharmaceutical sponsors and CROs seeking faster, more diverse enrollment.

Companies that use MedVector

Customer profile

Ideal customer profiles3 records

MedVector technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MedVector partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

MedVector competitors and assessment

Company assessment

Direct peers

  • ObvioHealth: Fully decentralized clinical trial platform combining telehealth, connected devices, and home-based nurse visits for sponsors. Comparable as a DCT vendor competing for the same hybrid visit and remote monitoring budgets.
  • Curebase: Decentralized clinical trial software platform enabling sponsors to run studies in participants' homes with connected devices and remote coordinators. Comparable to MedVector as a competing DCT platform for pharma/CRO customers.
  • Science 37: Decentralized clinical trial platform offering telehealth, in-home nurse visits, and connected devices for remote trial conduct. Directly comparable to MedVector as a DCT infrastructure player; the two compete for the same pharma/CRO sponsors seeking remote visit capabilities.
  • THREAD Research: DCT and eCOA platform supporting decentralized study execution, remote visits, and connected device integrations. Comparable as a competing DCT infrastructure provider in the same pharma/CRO market.
  • Medable: Patient-centric DCT platform providing eConsent, eCOA, telehealth, and remote data capture. Comparable to MedVector as a competing DCT infrastructure vendor targeting pharma sponsors and CROs.

Broad incumbents

  • Veeva Systems: Enterprise cloud software provider for the life sciences industry, including CTMS, EDC, and eTMF used by clinical trial sponsors and CROs. Comparable as an adjacent incumbent whose ecosystem decisions shape DCT adoption and integration paths.
  • IQVIA: Global CRO and clinical technology services provider with a dedicated decentralized clinical trial practice. Comparable as a broad incumbent offering site-less and hybrid trial services to pharma sponsors.
  • Signant Health: Clinical trial technology provider offering eCOA, eConsent, patient engagement, and decentralized trial solutions. Comparable as an incumbent DCT/eCOA vendor competing for shared sponsor budgets.
  • Clario: Large clinical trial technology vendor offering eCOA, cardiac safety, imaging, and decentralized trial solutions. Comparable as a broader incumbent offering overlapping DCT/remote visit capabilities to the same pharma/CRO buyers.

Emerging players

  • Florence Healthcare: Clinical trial site enablement platform providing eRegulatory, eISF, and remote site connectivity tools. Comparable as an emerging enabler focused on site-side workflow, overlapping with MedVector's site-preserving positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

MedVector social profiles

Digital presence

MedVector compliance and trust

Trust signal

Compliance3 records

MedVector financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MedVector leadership team

Management profile

Number of profiles

Profiles12 records

MedVector subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MedVector funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MedVector M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedVector

What does MedVector do?

MedVector provides a proprietary telemedicine platform, Prime-Control Technology, that enables clinical trial sites to virtually monitor subjects face-to-face at their local healthcare providers' offices without triggering new clinical trial sites or investigators. MedVector ships a shoebox-sized plug-and-play device to the subject's local HCP so a Principal Investigator (PI) can run the session remotely while the local nurse serves as the PI's "hands" for vitals, blood draws, and procedures. Source data is still entered into the trial site's EDC by the investigator team, preserving Good Clinical Practice (GCP).

Is MedVector a public or private company?

MedVector is a private company. It is classified as venture growth investor backed and is currently operating.

When was MedVector founded?

MedVector was founded in 2017. It employs 11 to 50 people.

Where is MedVector based?

MedVector is headquartered in El Segundo, United States, in the North America region.

How does MedVector make money?

Two revenue lines are on record. Clinical Trial Expansion Services for Pharma Sponsors and CROs are the primary driver. The others are startEngine Equity Crowdfunding.

Who are MedVector's main competitors?

Direct peers on record are ObvioHealth, Curebase, Science 37, THREAD Research and Medable. Broad incumbents are Veeva Systems, IQVIA, Signant Health and Clario. Florence Healthcare is listed as an emerging player.

Does MedVector have an API?

No public API is recorded for MedVector.

What industry is MedVector in?

MedVector's product category is Decentralized Clinical Trial Technology. Its primary akta.pro industry code is HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity), with a secondary code of HLALACAK, Pharmacy/Medication Management & Virtual MTM (Payer-Sponsored). Its NAICS code is 62111 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LinkedIn#covid19 #telemedicineMedVector engaged Karten Design to develop a patient recruitment solution for its telemedicine platform to accelerate clinical studies and medicine market entry. The company reported that the design was delivered within three months, aiming to increase participation in life-saving advanced medicine trials. This collaboration highlights the use of specialized design services to support rapid product development in the healthcare sector.StartEngineInvest in MedVectorMedVector is raising capital through a crowdfunding campaign on StartEngine to expand its telemedicine platform designed to accelerate clinical trial enrollment by connecting patients with local physicians. The company has raised $3.5 million to date, secured partnerships with the State of Delaware’s Health Information Network and Blood Centers of America, and holds non-disclosure agreements with nine of the top 15 pharmaceutical companies.Business Wire BlogMedVector to Clarify Misunderstood FDA Guidance at J.P. Morgan Healthcare ConferencesMedVector plans to clarify its interpretation of FDA guidance regarding telemedicine and patient location during the J.P. Morgan Healthcare Conference, arguing that current industry interpretations hinder clinical trial enrollment. The company's approach involves engaging treating physicians to connect with qualified patients virtually at clinical trial sites, a strategy validated by former FDA advisor Jonathan Helfgott.StartEngineInvest in MedVector - Telemedicine for Clinical TrialsMedVector, a telemedicine platform for clinical trials, aims to accelerate the drug approval process by connecting participants globally to clinical sites, thus increasing participation and speeding up FDA approvals. The company is currently raising funds via a crowdfunding offering with a valuation of approximately $10.02 million.PharmaLiveCraig Lipset Named as MedVector Board Member and Executive AdvisorCraig Lipset joined MedVector as board member and executive advisor, bringing his clinical trials expertise. He will provide strategic insights and facilitate collaborations with CROs and pharma. The company's Prime-Control platform aims to expand trial participation beyond existing sites.The Healthcare InsightsScott Stout: Driven to Expand Clinical Trials Beyond Trial SitesMedVector, a clinical trial technology company founded by Scott Stout, has developed a telemedicine platform that allows non-participating physicians to enroll patients in clinical trials without requiring them to visit central research sites. This approach aims to accelerate drug development and improve patient diversity by connecting sponsors with millions of potential subjects through existing local healthcare networks.LA City GuideMeet Scott Stout of MedVector Clinical Trials in West Side – Voyage LA Magazine | LA City GuideScott Stout introduces MedVector Clinical Trials, a startup that connects patients to clinical studies via portable telemedicine devices and a network of partner hospitals. The company aims to accelerate trial enrollment and generate revenue for local hospitals by eliminating geographic barriers and upfront costs associated with traditional clinical trials.LA City GuideMeet Scott Stout of MedVector Clinical Trials in West Side – Voyage LA Magazine | LA City GuideScott Stout founded MedVector Clinical Trials, a telemedicine-based platform that connects patients in partner hospitals to clinical trial sites, enabling local facilities to generate revenue without upfront costs or patient loss. The company utilizes proprietary portable telemedicine devices and has secured support from a private equity lead investor and an exclusive partnership with a telemedicine provider.